KRASG12C-positive NSCLC and CRC
Two-dose recombinant viral vector vaccine
The vaccine is well-tolerated, easily distributed, storable at refrigerator temperatures and easily administered.
There is some concern about its efficacy, which is as low as 59.5% as per protocol and as high as 90% with a prime-boost regimen that is not included in the planned protocol. Data are lacking for older patients (>55 years).
Access our global intelligence, advanced analytics and global team of experts.